First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”

Rhea-AI Summary

First Wave BioPharma (NASDAQ: FWBI) announced its participation in the BIO Partnering @ JPM conference, scheduled from January 9-12, 2023, in San Francisco. The company will engage in one-on-one meetings with investors and pharmaceutical firms to present its clinical development strategies and recent achievements. First Wave is focused on developing non-systemic therapies for gastrointestinal diseases, including a pipeline featuring adrulipase and niclosamide. For more information, visit www.firstwavebio.com.

BOCA RATON, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the company will participate in BIO Partnering @ JPM being held January 9-12, 2023 in San Francisco.

Details of the events are as follows:

Event:	BIO Partnering @ JPM
Date:	January 9-12, 2023
Registration:	https://www.bio.org/events/bio-partnering-jpm/registration

During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones. 

About First Wave BioPharma, Inc. 
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

Forward-Looking Statement 
This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to regain and maintain compliance with Nasdaq’s continued listing criteria; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information: 
First Wave BioPharma, Inc. 
777 Yamato Road, Suite 502 
Boca Raton, FL 33431 
Phone: (561) 589-7020 
info@firstwavebio.com 

Media contact: 
Tiberend Strategic Advisors, Inc. 
David Schemelia 
(609) 468-9325 
dschemelia@tiberend.com 

FAQ

What is the date of the BIO Partnering @ JPM event for First Wave BioPharma?

The BIO Partnering @ JPM event will take place from January 9-12, 2023.

Where is First Wave BioPharma's BIO Partnering @ JPM event participation happening?

First Wave BioPharma will participate in the BIO Partnering @ JPM event in San Francisco.

What does First Wave BioPharma focus on in its clinical development?

First Wave BioPharma specializes in targeted, non-systemic therapies for gastrointestinal diseases.

Which proprietary technologies is First Wave BioPharma developing?

First Wave BioPharma is developing adrulipase and niclosamide for various gastrointestinal conditions.

How can investors and pharmaceutical companies meet with First Wave BioPharma during the event?

Investors and pharmaceutical companies can schedule one-on-one meetings with First Wave BioPharma's management team during the BIO Partnering @ JPM conference.